ADPT · Adaptive Biotechnologies Corporation

Current Thesis

Adaptive's measurable-residual-disease (MRD) franchise the clonoSEQ test is inflecting from a chronic cash-burner into a self-funding growth story just as the medtech-diagnostics narrative goes public. The May 5 print showed MRD revenue +53% YoY, management raised the full-year MRD guide, and ASCO/EHA data running through June 14 is reinforcing clonoSEQ as the default response endpoint across the myeloma/lymphoma drug boom. The theme is accelerating and the tape sits near 52-week highs but still under the $21+ analyst band strength here is the setup, not a reason to wait, though the conference catalyst is already unfolding in the price.

Bull Case

• Q1 2026 (reported May 5): total revenue $70.9M, +35% YoY; the MRD segment did $67.1M, +53% YoY, and is now ~95% of revenue.
• clonoSEQ test volume hit 32,595 in Q1 2026, +41% YoY; the FY2026 framework calls for >30% volume growth the unit engine, not just price/mix, is accelerating.
• Profitability inflection is real: Q1 adjusted EBITDA loss narrowed to -$2.5M from -$12.7M a year prior; FY2025 adjusted EBITDA was +$12.2M vs -$80.4M in 2024; management targets positive company-wide adjusted EBITDA AND free cash flow by end-2026.
• Guidance raised on the May 5 print: FY2026 MRD revenue lifted to $260–270M (+22–27%); the first U.S. primary-endpoint pharma milestone ($9.0M) was recognized in Q1.
• Balance sheet covers the runway: $237.2M cash and marketable securities at March 31 2026 enough to reach self-sustaining without an equity raise.
• ASCO (May 29–Jun 3) + EHA (Jun 11–14): clonoSEQ featured in 33 presentations (1 plenary, 14 orals) across MM/CLL/ALL/lymphoma CEPHEUS, MONUMENTAL-3, inMMyCAR embedding MRD as the endpoint for the bispecific/CAR-T/quadruplet wave.
• Sell-side marks sit above spot: TD Cowen $21, BTIG $22, JPMorgan $21 (Overweight), consensus ~$21.3 vs an ~$18.4 tape.

Bear Case

• The stock has roughly doubled off its $9.90 52-week low to press the $20.76 high; the ASCO/EHA validation leg is happening in real time, so a chunk of the "moat confirmation" is already in the price.
• Still not GAAP-profitable "positive adjusted EBITDA + FCF by year-end" is a target, not a result. Any slippage resets the entire inflection thesis the multiple is leaning on.
• Revenue concentration: ~95% of the top line is one product line. Pharma milestone revenue ($9.0M in Q1) is lumpy and flatters the optics of the growth rate.
• The Immune Medicine segment (immunoSEQ, the Genentech TCR drug-discovery partnership) remains optionality and overhead, not a driver no needle-mover yet.
• Competitive/reimbursement risk: Natera and Guardant are pushing tissue-free and ctDNA MRD; a payer or guideline tilt toward a rival assay pressures clonoSEQ volume directly.
• Social velocity already spiked sharply into the conference window, implying the easy narrative-discovery phase is partly spent rather than just beginning.

Setup & Price Structure

• Tape: ~$18.44 (Jun 12 close), intraday $18.38–$20.32. Sequence Jun 10 $17.03 → Jun 11 $18.79 → Jun 12 a three-day push straight into the EHA window.
• 52-week range $9.90–$20.76; price sits in the top decile of that range, ~11% under the high. Market cap ~$2.95B.
• Structure is a multi-month base-and-breakout off single digits; the trend stays intact while it holds the rising 20-week area (roughly the mid-teens). The immediate technical test is whether EHA data clears $20.76 or the move stalls and digests under it.
• It is not yet stretched against the sell-side: trading below the $20.2–$23.1 analyst band, unlike a name running 50% above its price targets where mean-reversion is the base case.

Catalyst Calendar (next 30 days)

• EHA Congress, Stockholm June 11–14 2026: live clonoSEQ readouts (MM/CLL/ALL/lymphoma); the final orals and plenary land through June 14 the active near-term driver.
• Post-conference KOL commentary and medical-press cycle late June 2026 (est.), the follow-through that either extends or fades the conference bid.
• No company earnings inside the window; the Q2 2026 print is scheduled for August 5 2026 the next binary, ~7 weeks out and outside the 30-day window.
• No FDA/PDUFA event dated in the window; clonoSEQ is already FDA-cleared, CE-marked, and Medicare-covered, so coverage status is a base, not a pending catalyst.

What Would Change Our Mind

• A weekly close back below ~$16 (the rising 20-week line / breakout shelf) momentum structure lost; stand aside until a fresh higher-low rebuilds the base.
• The Aug 5 Q2 print showing MRD revenue growth decelerating toward the low-20s% or the $260–270M FY guide walked back rather than raised again.
• The year-end positive adjusted-EBITDA / free-cash-flow target explicitly pushed out that is the load-bearing fundamental claim.
• A payer or guideline move favoring a competing MRD/ctDNA assay (Natera, Guardant) over clonoSEQ.
• Theme rotation from accelerating to crowded: mainstream financial-press coverage plus social cresting with no new clinical or guidance catalyst left to carry it the saturation tell.

Correlation Notes

• Trades inside the MRD/liquid-biopsy diagnostics complex with Natera (NTRA), Guardant (GH), and Exact Sciences (EXAS) shared reimbursement and guideline-adoption beta moves the cohort together.
• Demand is a derivative of the hematology drug boom: clonoSEQ volume tracks myeloma/lymphoma trial activity at J&J, Pfizer, GSK, and Roche/Genentech, since MRD is the response endpoint those programs report.
• Belongs to the broader medtech-devices-diagnostics theme alongside names such as Butterfly Network (BFLY); theme-level social acceleration lifts the group, which also means a theme-wide rollover would drag it lower regardless of clonoSEQ's own numbers.
• The Genentech TCR partnership ties a slice of the Immune Medicine narrative to Roche pipeline newsflow.